GlassScriptPhysician profile
Wai H Lee
NPI 1265435861
$320,512.28
in general payments reported to CMS, 2019-2025
36 companies · $23.96 in 2025
The $23.96 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $41K · 2021: $55K · 2022: $57K · 2023: $79K · 2024: $26K · 2025: $23.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Honoraria: $20K · Travel and Lodging: $10K · Food and Beverage: $4,925 · Consulting Fee: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,909.00 |
| Honoraria | $20,330.00 |
| Travel and Lodging | $10,276.02 |
| Food and Beverage | $4,924.53 |
| Consulting Fee | $3,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57,138.98 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $50,568.33 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $34,528.05 | 2019-2024 | Farxiga, Brilinta |
| Lilly USA, LLC | $33,855.75 | 2020-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $30,275.39 | 2019-2024 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $25,005.11 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $23,753.05 | 2021-2023 | |
| Esperion Therapeutics, INC. | $21,971.45 | 2020-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $17,093.85 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $9,050.57 | 2019-2023 | |
| Amgen INC. | $7,771.63 | 2019-2024 | Repatha |
| Regeneron Healthcare Solutions, INC. | $3,583.56 | 2019-2024 | Evkeeza |
| Merck Sharp & Dohme LLC | $3,350.95 | 2021-2024 | Verquvo |
| Celgene Corporation | $600.00 | 2022 | |
| Pfizer INC. | $582.89 | 2019-2024 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wai Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.